Exhibit 99.1 Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update • Met all endpoints in Phase 3 pivotal study for Anaphylm™ (epinephrine) Sublingual Film in first quarter 2024 when compared to EpiPen® and other injectors used for the treatment of anaphylaxis • On track to complete Anaphylm temperature/pH study in second quarter 2024 • Received positive feedback from FDA on Anaphylm self-administration and allergen exposure protocols; remains on track to complete ...